What is the Radioembolization Therapy Market Size in 2026?

The global radioembolization therapy market was valued at USD 1.19 billion in 2025 and is projected to increase to USD 1.26 billion in 2026. Over the forecast period, the market is expected to reach approximately USD 2.15 billion by 2035, expanding at a CAGR of 7.64% from 2026 to 2035.

Market growth is primarily driven by

Rising global prevalence of liver cancer
Growing demand for minimally invasive cancer treatments
Technological advancements in interventional oncology
Increasing adoption of targeted radiation therapies
Expanding healthcare infrastructure in emerging economies

Read Also: AI in Medical Billing Market

What is the Radioembolization Therapy Market?

Radioembolization therapy is a targeted internal radiation treatment primarily used to treat primary and metastatic liver cancer. The therapy involves delivering radioactive microspheres—commonly Yttrium-90 (Y-90)—directly into liver tumors through the hepatic artery.

This therapy:

Combines embolization with radiotherapy
Delivers high-dose radiation directly to tumors
Minimizes damage to surrounding healthy tissues
Serves as a treatment option for unresectable liver cancers

Radioembolization therapy is considered a specialized segment within interventional oncology, offering effective palliative and disease-control solutions.

Key Takeaways

North America dominated the global market in 2025.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
Yttrium-90 microspheres led the product segment in 2025.
Holmium-166 microspheres are projected to grow at the highest CAGR.
Selective Internal Radiation Therapy (SIRT) held the majority revenue share in 2025.
Segmental radioembolization is expected to grow rapidly.
Trans arterial radioembolization dominated the technology segment.
Primary liver cancer was the leading application in 2025.
Metastatic liver cancer is forecasted to grow the fastest.

Role of Technology in Market Growth

Technological advancements are central to improving precision, safety, and patient outcomes in radioembolization therapy.

Advanced Microsphere Technology

Sophisticated glass and resin microspheres enable accurate delivery of high-dose radiation directly to tumors.

Major systems include products developed by companies such as:

Sirtex Medical
Boston Scientific Corporation

Imaging Integration

Advanced imaging technologies such as:

SPECT
PET
MRI
3D imaging

help optimize tumor localization, dose planning, and treatment verification.

AI & Machine Learning

Artificial intelligence enhances:

Dose calculation accuracy
Treatment planning
Patient outcome prediction
Personalized therapy mapping

These advancements reduce hospital visits and enable faster, sometimes single-day, procedures.

Radioembolization Therapy Market Trends

Growing Demand for SIRT

Selective Internal Radiation Therapy (SIRT) is gaining popularity due to its high effectiveness in treating unresectable hepatocellular carcinoma.

Personalization & Voxel-Based Dosimetry

Advanced voxel-based radiation mapping allows improved tumor targeting while reducing cold spots and minimizing side effects.

Shift Toward Minimally Invasive Procedures

Patients and clinicians increasingly prefer minimally invasive treatments over conventional surgery or systemic chemotherapy due to:

Lower complication risks
Faster recovery
Improved quality of life

Segmental Insights

By Product Type

Yttrium-90 Microspheres Dominated in 2025

The Yttrium-90 (Y-90) microspheres segment led the market due to:

Widespread clinical usage
FDA approvals
High physician familiarity
Strong global distribution networks

These microspheres are available in glass and resin variants and offer effective tumor control, even in patients with portal vein thrombosis.

Key manufacturers include:

Sirtex Medical
Nordion Inc.

Holmium-166 Microspheres to Grow at Fastest CAGR

Holmium-166 microspheres are gaining momentum due to their theranostic capabilities. They allow:

Precise pre-treatment imaging
Real-time dosimetry verification
MRI compatibility
Improved safety and tumor-specific dosing

By Procedure Type

Selective Internal Radiation Therapy (SIRT) Led in 2025

SIRT, also known as Transcatheter Arterial Radioembolization (TARE), accounted for the largest revenue share.

It is widely used for:

Hepatocellular carcinoma (HCC)
Liver metastases
Unresectable tumors

SIRT is increasingly integrated with immunotherapy, opening new therapeutic pathways.

Segmental Radioembolization to Grow Rapidly

Segmental radioembolization focuses on delivering ablative doses to localized tumors, offering:

Curative-intent treatment
Reduced radiation-induced liver disease
Better tumor control
Hypertrophy of healthy liver tissue

By Technology

Trans Arterial Radioembolization Dominated in 2025

This segment held the largest share due to:

Targeted Y-90 delivery
Fewer side effects compared to chemoembolization
Ability to treat portal vein thrombosis
Effective tumor downstaging

SIRT Technology to Witness Fastest Growth

SIRT’s expanding applications, improved outcomes, and rising adoption in inoperable cases are driving rapid growth.

By Application

Primary Liver Cancer Led the Market in 2025

Primary liver cancer is dominant due to:

Rising hepatocellular carcinoma cases
Superior tumor targeting
Minimally invasive palliative care options

Metastatic Liver Cancer to Grow Fastest

Growth is driven by:

Increasing colorectal cancer metastases
Strong clinical evidence supporting Y-90 efficacy
Longer time-to-progression compared to chemotherapy

Competitive Landscape

Key players operating in the global radioembolization therapy market include:

Sirtex Medical
Boston Scientific Corporation
Terumo Corporation
Merit Medical Systems, Inc.
ABK Biomedical Inc.
TriSalus Life Sciences
Guerbet
Varian Medical Systems
Cook Medical Inc.

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com

About
Latest Posts

ritika jankar